Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

KBR
koreabiomed.com > news > articleViewAmp.html

Samsung Bioepis posts 6% growth in H1 revenue, operating profit

2+ day, 7+ hour ago   (328+ words) Samsung Bioepis reported higher revenue and operating profit for the first half of 2026, driven by continued growth in its global biosimilar business, while maintaining its outlook for double-digit annual sales growth despite a weaker second quarter. According to earnings released…...

KBR
koreabiomed.com > news > articleView.html

Oscotec founder's succession completed as son becomes largest shareholder

2+ day, 10+ hour ago   (309+ words) Oscotec Inc. has completed the inheritance process following the death of its founder and former Chairman Kim Jung-geun, with his eldest son Kim Seong-yeon becoming the company's new largest shareholder. The company said Thursday that heir Kim Seong-yeon and related…...

KBR
koreabiomed.com > news > articleView.html

Severance Hospital to lead ₩2.9 bil. stem cell study for knee osteoarthritis

2+ day, 9+ hour ago   (452+ words) Severance Hospital said Friday it has launched a stem cell-based advanced regenerative medicine clinical study for patients with knee osteoarthritis. The hospital said it has been selected for the 2026 Second Advanced Regenerative Medicine Clinical Research Promotion Program, organized by the…...

KBR
koreabiomed.com > news > articleView.html

[News Analysis] Kolon faces leadership test after TG-C's first US phase 3 setback

2+ day, 11+ hour ago   (1111+ words) Kolon TissueGene's osteoarthritis cell and gene therapy candidate TG-C (formerly Invossa) has failed to meet its co-primary endpoints in its first U.S. phase 3 clinical trial. The setback put the Kolon Group's ability to navigate one of the most critical crises in…...

KBR
koreabiomed.com > news > articleView.html

Hanmi showcases AI platform behind clinical-stage obesity drug at ISMB

2+ day, 11+ hour ago   (459+ words) Hanmi Pharmaceutical said Friday it has developed a proprietary AI platform capable of predicting the pharmacological activity of subtle protein sequence variations and recommending optimal molecular designs for drug candidates, marking a significant step in AI-driven drug discovery. The achievement…...

KBR
koreabiomed.com > news > articleView.html

Severe IgA nephropathy keeps failing to gain rare disease status, as officials cite need for stronger evidence

2+ day, 10+ hour ago   (774+ words) Efforts by the medical community to designate severe IgA nephropathy as a rare disease to improve patient access to treatment have repeatedly stalled. Experts attribute it to a policy disconnect between the rare disease designation system and reimbursement criteria under…...

KBR
koreabiomed.com > news > articleViewAmp.html

SNUH study reveals how common EZH1 mutation fuels thyroid cancer

2+ day, 10+ hour ago   (335+ words) Researchers at Seoul National University Hospital (SNUH) have uncovered how the EZH1 Q571R mutation, a genetic alteration frequently found in thyroid cancer, promotes tumor growth by silencing key tumor suppressor genes. The study identified the mutation's enhanced ability to condense chromatin as…...

KBR
koreabiomed.com > news > articleView.html

Appeals court acquits woman, upholds doctors' murder convictions in Korea's 36-week abortion case

2+ day, 8+ hour ago   (841+ words) A Korean appeals court has acquitted a woman who underwent an abortion at about 36 weeks of pregnancy, while upholding murder convictions against the medical professionals who performed the procedure. Human rights group Amnesty International criticized the ruling, arguing that it…...

KBR
koreabiomed.com > news > articleViewAmp.html

Long-term steroid, antimalarial use warrants regular eye exams, doctor says

2+ day, 9+ hour ago   (214+ words) Patients who take corticosteroids or antimalarial medications over an extended period to treat chronic conditions such as rheumatoid arthritis or lupus should not overlook one important part of their healthcare routine: regular eye examinations. Corticosteroids are widely used to control…...

KBR
koreabiomed.com > news > articleViewAmp.html

HLB says FDA review of bile duct cancer drug lirafugratinib enters final stage

2+ day, 13+ hour ago   (283+ words) HLB, a Korean cancer drug developer, said Friday that it has completed a late-cycle meeting with the U.S. FDA as part of the agency's review of lirafugratinib for second-line treatment of bile duct cancer, with no major issues raised that would…...